United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2013_register executive 2013-07-06 article Notices D09002ee1c7fb4613 D09002ee1c7fb4698 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, indicates that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a start-up exclusive commercialization license to practice the inventions embodied in: (a) Technology families E-047-1994/0 and E-047-1994/1, including U.S. Patent 5,635,599 entitled "Proteins Comprising Circularly Permuted Ligands" [HHS Ref. E-047-1994/0-US-01], PCT Application PCT/ US95/04468 entitled "Circularly Permutated Ligands and Circularly Permuted Chimeric Molecules" [HHS Ref. E-047-1994/0-PCT-02], European Patent 0754192 entitled "Proteins Comprising Circularly Permuted Ligand" [HHS Ref. E-047-1994/0-EP-15, validated in Austria, Belgium, France, Italy, Liechtenstein, The Netherlands, Spain, Switzerland and the United Kingdom], Canadian Patent 2187283 entitled "Proteins Comprising Circularly Permuted Ligands" [HHS Ref. E-047-1994/0-CA-14], Australian Patent 694211 entitled "Proteins Comprising Circularly Permuted Ligands" [HHS Ref. E-047-1994/0-CA-14], and U.S. Patent 6,011,002 entitled "Circularly Permutated Ligands and Circularly Permuted Chimeric Molecules" [HHS Ref. E-047-1994/1-US-01]; (b) Technology family E-021-2010/0, including U.S. Patent Application 61/105,408 entitled "Targeted Cargo Protein Combination Therapy" [HHS Ref. E-021-2010/0-US-01] and U.S. Patent Application 12/ 579,281 entitled "Targeted Cargo Protein Combination Therapy" [HHS Ref. E-021-2010/0-US-02]; and all related continuing and foreign patents/patent applications for these technology families, to Medicenna Therapeutics, Inc. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective start-up exclusive commercialization license territory may be worldwide, and the field of use may be limited to: 78 FR 40757 https://www.govinfo.gov/app/details/FR-2013-07-08/2013-16237 2013-16237 fr08jy13-77 4140-01-P https://www.govinfo.gov/app/details/FR-2013-07-08/2013-16237 https://www.govinfo.gov/content/pkg/FR-2013-07-08/html/2013-16237.htm https://www.govinfo.gov/content/pkg/FR-2013-07-08/pdf/2013-16237.pdf 1 p. 40757 40757 78 FR 40757 Prospective Grant of Start-Up Exclusive Commercialization License: The Development of a Circularly Permuted IL4-Targeted Pseudomonas Exotoxin A (cpIL4-PE38KDEL) for the Treatment of Cancers and Urological Disorders; Federal Register Vol. 78, Issue NOTICE 2013-16237 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2013-07-23 4140-01-P 2013-16237 Notice.

This notice, in accordance with 35 U.S.C. 209 and 37 CFR Part 404, indicates that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a start-up exclusive commercialization license to practice the inventions embodied in: (a) Technology families E-047-1994/0 and E-047-1994/1, including U.S. Patent 5,635,599 entitled "Proteins Comprising Circularly Permuted Ligands" [HHS Ref. E-047-1994/0-US-01], PCT Application PCT/ US95/04468 entitled "Circularly Permutated Ligands and Circularly Permuted Chimeric Molecules" [HHS Ref. E-047-1994/0-PCT-02], European Patent 0754192 entitled "Proteins Comprising Circularly Permuted Ligand" [HHS Ref. E-047-1994/0-EP-15, validated in Austria, Belgium, France, Italy, Liechtenstein, The Netherlands, Spain, Switzerland and the United Kingdom], Canadian Patent 2187283 entitled "Proteins Comprising Circularly Permuted Ligands" [HHS Ref. E-047-1994/0-CA-14], Australian Patent 694211 entitled "Proteins Comprising Circularly Permuted Ligands" [HHS Ref. E-047-1994/0-CA-14], and U.S. Patent 6,011,002 entitled "Circularly Permutated Ligands and Circularly Permuted Chimeric Molecules" [HHS Ref. E-047-1994/1-US-01]; (b) Technology family E-021-2010/0, including U.S. Patent Application 61/105,408 entitled "Targeted Cargo Protein Combination Therapy" [HHS Ref. E-021-2010/0-US-01] and U.S. Patent Application 12/ 579,281 entitled "Targeted Cargo Protein Combination Therapy" [HHS Ref. E-021-2010/0-US-02]; and all related continuing and foreign patents/patent applications for these technology families, to Medicenna Therapeutics, Inc. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective start-up exclusive commercialization license territory may be worldwide, and the field of use may be limited to:

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 23, 2013 will be considered. Prospective Grants of Start-Up Exclusive Commercialization Licenses: Development of a Circularly Permuted IL4-Targeted Pseudomonas Exotoxin A (cpIL4PE38KDEL) for Treatment of Cancers and Urological Disorders , lambertsond@mail.nih.gov Vol. 78, no. 130 Office of the Federal Register, National Archives and Records Administration 2013-07-08 continuing daily deposited born digital 318 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2013-07-08 P0b002ee1851293cc 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr08jy13 https://www.govinfo.gov/app/details/FR-2013-07-08 https://www.govinfo.gov/content/pkg/FR-2013-07-08/pdf/FR-2013-07-08.pdf https://www.govinfo.gov/content/pkg/FR-2013-07-08/xml/FR-2013-07-08.xml fdlp 40625 40933 DGPO 2013-07-06 2024-06-03 FR-2013-07-08 machine generated eng FR FR-2013-07-08 78 130